The HER2-positive revolution isn't coming. It's here.


In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026.


From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care.


Can we safely eliminate carboplatin?

Can biomarkers tell us who needs less treatment?

Is a chemotherapy-free future finally a reality for certain patients?


The future of HER2-positive breast cancer is being written right now.


🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music


#BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör Dr. Jason Mouabbi and Dr. Paolo Tarantino. Innehållet i podden är skapat av Dr. Jason Mouabbi and Dr. Paolo Tarantino och inte av, eller tillsammans med, Poddtoppen.